Sichuan Biokin Pharmaceutical Co.,Ltd. Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2018 - 2015
Period Ending	Sep '24 Sep 5, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2018 - 2015
Market Capitalization	62,773	56,100	-	-	-	-	Upgrade
Enterprise Value	58,033	56,019	-	-	-	-	Upgrade
Last Close Price	156.54	139.90	-	-	-	-	Upgrade
PE Ratio	14.88	-71.74	-	-	-	-	Upgrade
PS Ratio	10.80	99.84	-	-	-	-	Upgrade
PB Ratio	13.00	369.39	-	-	-	-	Upgrade
P/FCF Ratio	13.43	-80.45	-	-	-	-	Upgrade
P/OCF Ratio	15.36	-91.17	-	-	-	-	Upgrade
EV/Sales Ratio	10.00	99.70	-	-	-	-	Upgrade
EV/EBITDA Ratio	13.42	-76.98	-	-	-	-	Upgrade
EV/EBIT Ratio	13.64	-71.31	-	-	-	-	Upgrade
EV/FCF Ratio	12.42	-80.34	-	-	-	-	Upgrade
Debt / Equity Ratio	0.24	4.53	0.59	0.86	0.33	0.46	Upgrade
Debt / EBITDA Ratio	0.27	-	-	-	5.68	24.32	Upgrade
Debt / FCF Ratio	0.25	-0.99	-1.87	-1.60	2.38	28.05	Upgrade
Asset Turnover	1.31	0.33	0.48	0.80	0.95	-	Upgrade
Inventory Turnover	1.70	2.00	2.59	2.75	2.82	-	Upgrade
Quick Ratio	2.82	0.52	1.73	0.62	0.89	0.91	Upgrade
Current Ratio	2.97	0.74	1.93	0.90	1.07	1.07	Upgrade
Return on Equity (ROE)	155.17%	-143.77%	-44.62%	-25.51%	8.62%	-	Upgrade
Return on Assets (ROA)	60.11%	-28.74%	-14.01%	-10.00%	-1.34%	-	Upgrade
Return on Capital (ROIC)	74.88%	-42.30%	-19.63%	-16.33%	-2.33%	-	Upgrade
Earnings Yield	6.72%	-1.39%	-	-	-	-	Upgrade
FCF Yield	7.44%	-1.24%	-	-	-	-	Upgrade
Payout Ratio	0.57%	-	-	-	26.28%	389.13%	Upgrade
Buyback Yield / Dilution	-5.11%	-10.56%	-1.38%	-3.64%	10.86%	-276.33%	Upgrade
Total Shareholder Return	-5.11%	-10.56%	-1.38%	-3.64%	10.86%	-276.33%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.